Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Cantor Fitzgerald upgraded Cartesian Therapeutics (RNAC) to Overweight from Neutral with a $16 price target Cartesian had no major surprises in its Q4 earnings report, as catalyst timing remains the same for Descartes-08, the analyst tells investors in a research note. Despite the upgrade, Cantor’s thesis hasn’t changed, but thinks these factors — the competitive space and the potential for later line usage if priced high — are already priced in.